Navigation Links
Acute Coronary Syndrome (ACS) Drug Market
Date:7/5/2011

9.1 Pipeline Products in the ACS Treatment Industry

9.2 The Unmet Needs of the ACS Market have Encouraged R&D

9.3 Oral Anticoagulants in Development: Progress and Setbacks

9.3.1 Apixaban, Bristol-Myers Squibb/Pfizer

9.3.1.1 Filed for VTE, but Setback for Development in ACS Patients

9.3.2 Xarelto (Rivaroxaban), Bayer HealthCare Pharma/Johnson & Johnson Pharmaceutical Research & Development

9.3.3 Pradaxa (Dabigatran), Boehringer Ingelheim

9.3.4 TAK-442 (Letaxaban), Takeda Pharmaceuticals

9.4 Novel Parenteral Anticoagulants: Offering Advantages over the Current Standard of Care?

9.4.1 Otamixaban, Sanofi-Aventis

9.4.1.1 Rapid Onset of Action and Short Half-Life

9.4.2 REG1, Regado Biosciences

9.4.2.1 First Aptamer Drug for the Treatment of ACS

9.4.2.2 In Phase II Clinical Trials for ACS

9.5 Direct ADP Receptor Antagonists: Providing Rapid Onset and Offset of Action

9.5.1 Brilinta (Ticagrelor), AstraZeneca

9.5.1.1 Rejected for Reimbursement in France: Another Setback after Delay of Approval in the US

9.5.1.2 Factors Favouring Brilinta: A New Class of Drug

9.5.2 Elinogrel (PRT128), Novartis/Portola Pharmaceuticals

9.5.3 Cangrelor, The Medicines Company

9.6 Thrombin Receptor Antagonists: Novel Antiplatelet Drugs

9.6.1 Vorapaxar, Merck & Co.

9.6.1.1 Setback for a Promising Candidate

9.6.2 E555 (Atopaxar), Eisai

9.7 Other Drugs in Development for ACS

10. Qualitative Analysis of the Industry and Market

10.1 Strengths and Weaknesses of the Sector

10.1.1 Increasing Prevalence of Disease Drives the Market

10.1.2 High Mortality Rates: Leading Cause of Death in Developed Countries

10.1.3 Available Treatments Have Been Successful in Reducing Mortality Rate

10.1.4 High Economic Cost of Disease

10.2 Opportunities and Threats

10.2.1 Deve
'/>"/>

SOURCE Reportlinker
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Financial Assistance Now Available for People with Acute Lymphoblastic Leukemia
2. Wake Forest Baptist Medical Center and Cornerstone Pharmaceuticals Present Interim Data From Phase I Trial of CPI-613 in Acute Myeloid Leukemia
3. AcelRx European Patent Covering its NanoTab® Sublingual Delivery Technology for Acute and Breakthrough Pain Pipeline Products Emerges From Opposition Period
4. NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction
5. Nile Therapeutics Receives Fast Track Designation for Cenderitide for Post-Acute Indication
6. International Medical Corps Team in Hardest-Hit Coastal Communities Finds Severe Shortages of Food, Water, Medicines; Acute Need for Mental Health Support
7. Nile Therapeutics Announces Plans to Pursue a Post-Acute Indication in Heart Failure
8. Allscripts Demonstrates Native Integration of Acute and Ambulatory Electronic Health Records at HIMSS
9. University Hospitals Selects Allscripts Electronic Health Record for 1,400 Physicians and Expands Sunrise™ Enterprise Acute Care EHR in Eight Hospitals
10. FDA Issues Complete Response Letter Regarding Acetadote® Supplemental New Drug Application for Acute Liver Failure
11. By 2019, the Acute Gout Drug Market Will Triple in Size While the Chronic Gout Drug Market Will Reach $1.83 Billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 AARP Foundation today announced it ... adults suffering from the severe cold weather that has gripped ... to helping those in need; so to support these emergency ... up to $250,000, which could mean up to $500,000 in ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... , January 15, 2014 BreedIT Corp ... exclusive worldwide distributor of highly sophisticated agro-breeding solutions for ... 7, 2014, the Company,s board of directors appointed chemistry ... as its new member of the board. ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... multi-year, multi-hospital retrospective database analysis,demonstrates RDS treatment ... improved neonatal,survival --, NAPA, Calif. and PARMA, ... today at the Pediatric Academic Societies' Annual ... Syndrome (RDS) have a nearly 20% better ...
... Inspire,Pharmaceuticals, Inc. (NASDAQ: ISPH) today announced results ... epinastine nasal,spray and placebo in patients with ... improvement in total nasal symptom score,dose-related effects ... higher,dose (0.1%) achieving statistical superiority over placebo., ...
Cached Medicine Technology:Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 2Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 3Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 4Preterm Infants with Respiratory Distress Syndrome: Incidence Rates,of Death when Treated with Surfactant Replacement Therapies 5Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4
(Date:4/18/2014)... School of Medicine researchers have been awarded two-year grants ... Nordisk announced this month. Of the 110 initial submissions ... Science Forum Program, only four projects were funded, three ... are Jonathan Powell, M.D., Ph.D.; G. William Wong, Ph.D.; ... a professor of oncology, will use his $500,000 proof ...
(Date:4/18/2014)... in French . ... and regenerative medicine. A team led by Ludwik Leibler ... Tech) and Didier Letourneur from the Laboratoire Recherche Vasculaire ... demonstrated that the principle of adhesion by aqueous solutions ... soft-tissue organs and tissues. This easy-to-use gluing method has ...
(Date:4/17/2014)... identified new pain relief targets that could be ... researchers at King,s College London made the discovery ... the periphery of the body. , Dr Marzia ... mechanisms underlying pain generation and our findings could ... effects." , One potential side effect of some ...
(Date:4/17/2014)... recent papers by a University of Colorado School ... develop treatments or vaccines for Dengue fever, West ... disease-causing flaviviruses. , Jeffrey S. Kieft, PhD, associate ... School of Medicine and an early career scientist ... recently published articles in the scholarly journals ...
(Date:4/17/2014)... (April 17, 2014) Doctors who treat patients ... lymphangioleiomyomatosis (LAM) can face an agonizing treatment decision. ... the disease and help relieve shortness of breath. ... and sirolimus can cause potentially fatal complications following ... Dr. Daniel Dilling, medical director of Loyola University ...
Breaking Medicine News(10 mins):Health News:Innovative strategy to facilitate organ repair 2Health News:Innovative strategy to facilitate organ repair 3Health News:New pain relief targets discovered 2Health News:CU researchers discover target for treating dengue fever 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3
... has been effective for inoperable liver cancer. It is a year since ... a 25 ... rate in either reducing tumour size or the number of tumours. Till ... tumours, who cannot be treated by any other means. ,TheraSphere ...
... who suffer from dementia benefit from music therapy. The therapy ... The trials have found that the therapy is popular with ... at Imperial College London are planning to carry out a ... has long term benefits for dementia sufferers. If their results ...
... with low birth weight can significantly improve survival rates, ... diseases. The research involved 1,154 full-term but smaller than ... 5 1/2 pounds or less. Mothers fed them supplements ... the 20 who died had not been receiving zinc ...
... sole franchisee for US based Medicine Shoppe International, with operations ... from list of its target for operations in the country. ... to expand its franchisee operations from the present 19 outlets ... has decided to put on hold the commencing of operations ...
... a heavy breakfast and a steaming cup of tea may increase ... fried food each morning are at twice the risk of ... to reduce the incidence of cancer is to begin the day ... ,Cancer of the oesophagus - the food pipe connecting the stomach ...
... are more likely to get diagnosed with the progressive brain ... the case, although some have suggested that the disease may ... before it manifests itself elsewhere. ,Dr Robert Abbott, ... effectively identify people with early or suspected disease or people ...
Cached Medicine News:Health News:Cut down on fries 2